The Biosafety Level-3 (BL-3) Core Facility is designed to provide an efficient, cost-effective, and safe environment for CFAR and other investigators involved in AIDS and AIDS-related research such that both ongoing projects will benefit and new collaborations will be fostered. Since culture of biohazardous pathogens including HIV, SIV, HTLV-I and virulent M. tuberculosis is an absolute requirement for many CFAR investigators, this facility is essential. The new BL-3 Facility (1127 sq ft) is scheduled for completion in October 1993, and is located on the 10th floor of the Biomedical Research Building, in the Division of Infectious Disease. The Facility has recently been equipped to the greater extent by the CWRU School of Medicine. Equipment includes 5 laminar flow hoods, centrifuges, incubators, -70C freezers, microscopes, thermal cycler and ELISA reader. The Facility is comprised of 6 rooms, the 3 largest for biohazardous activities. One room will be devoted to research involving virulent M. tuberculosis and another to HIV, SIV, and HTLV-I. Other rooms house common equipment. The BL-3 Core Facility will be administered by a BL-3 Advisory Group comprised of members of the CFAR; Dr. Rich (Director of the BL-3 Core Facility), Dr. LeGrice, and De. Lederman. Dr. Rich's laboratory is adjacent to the BL-3 Facility. Projects performed in the BL-3 Facility will be established beginning in funding year 02 to cover costs of the Facility such that by year 05, 70% of these will be generated by such fees. Multidisciplinary collaboration will be fostered by the BL-3 Core Facility by three main mechanisms: 1) Through interactions among users of the facility; 2) Through services rendered by a full-time research assistant in the facility including viral stock preparation, HIV infections of cells, p24 ELISAs, and teaching of these techniques to new investigators. 3) Quarterly meetings by all users and interested faculty discussing results obtained from experiments performed in the facility.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
1P30AI036219-04
Application #
6235260
Study Section
Project Start
1997-04-01
Project End
1998-03-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Mbonye, Uri; Wang, Benlian; Gokulrangan, Giridharan et al. (2018) Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation. J Biol Chem 293:10009-10025
Sayin, Ismail; Radtke, Andrea J; Vella, Laura A et al. (2018) Spatial distribution and function of T follicular regulatory cells in human lymph nodes. J Exp Med 215:1531-1542
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Martinez, Leonardo; Shen, Ye; Handel, Andreas et al. (2018) Effectiveness of WHO's pragmatic screening algorithm for child contacts of tuberculosis cases in resource-constrained settings: a prospective cohort study in Uganda. Lancet Respir Med 6:276-286
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Kityo, Cissy; Makamdop, Krystelle Nganou; Rothenberger, Meghan et al. (2018) Lymphoid tissue fibrosis is associated with impaired vaccine responses. J Clin Invest 128:2763-2773

Showing the most recent 10 out of 539 publications